Skip to main content

Table 5 Variability of selected biomarkers in stable subjects.

From: COPD association and repeatability of blood biomarkers in the ECLIPSE cohort

Biomarker COPD Subjects* Smoker Controls Non-smoker Controls All Subjects
CC-16 132/146 (90%) 29/35 (83%) 31/34 (91%) 192/215 (89%)
C-reactive protein 32/153 (21%) 7/36 (19%) 12/35 (34%) 51/224 (23%)
CCL24 51/144 (35%) 8/32 (25%) 16/35 (46%) 75/211 (36%)
Fibrinogen 139/156 (89%) 31/36 (86%) 35/36 (97%) 205/228 (90%)
Hepatocyte growth factor 57/152 (38%) 17/36 (47%) 19/36 (53%) 93/224 (42%)
Interleukin-6 55/147 (37%) 22/34 (65%) 24/36 (67%) 101/217 (47%)
Interleukin-8 67/141 (48%) 12/35 (34%) 13/33 (39%) 92/209 (44%)
Interleukin 12p40 64/124 (52%) 14/27 (52%) 20/30 (67%) 98/181 (54%)
CXCL10 86/152 (57%) 19/35 (54%) 23/34 (68%) 128/221 (58%)
CCL2 72/154 (47%) 22/36 (61%) 13/36 (36%) 107/226 (47%)
Matrix metalloproteinase-9 53/154 (34%) 8/36 (22%) 18/36 (50%) 79/226 (35%)
CCL23 93/154 (60%) 20/36 (56%) 23/36 (64%) 136/226 (60%)
Myeloperoxidase 52/154 (34%) 7/35 (20%) 15/36 (42%) 74/225 (33%)
CCL-18 53/135 (39%) 15/26 (58%) 15/35 (43%) 83/196 (42%)
Prolactin 47/148 (32%) 7/36 (19%) 9/35 (26%) 63/219 (29%)
Surfactant Protein D 107/145 (74%) 26/35 (74%) 30/34 (88%) 163/214 (76%)
  1. Expressed as a percentage of subjects in which the 3-month value was within 25% of the baseline value. *COPD subjects with exacerbations within 30 days of the 3-month visit or subjects using oral steroids within 14 days of the 3 month visit were excluded.